Anti-tumor necrosis factor therapies for psoriasis

Expert Review of Dermatology

Volumn 2, Issue 3, 2007, Pages 335-349

  Vena, Gino A ^a   Cassano, Nicoletta ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Adalimumab; Anti TNF; Biologic therapy; Efficacy; Etanercept; Infliximab; Mechanism of action; Pharmacokinetics; Psoriasis; Safety; TNF

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; GOLIMUMAB; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERFERON; MERCAPTOPURINE; METHOTREXATE; PARACETAMOL; PLACEBO; PREDNISONE; PSORALEN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIBAVIRIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ABSCESS; ANKYLOSING SPONDYLITIS; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTHRITIS; AUTOIMMUNE HEPATITIS; BACTERIAL INFECTION; BLOOD DYSCRASIA; BRONCHITIS; CD4 LYMPHOCYTE COUNT; CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DEMYELINATION; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG USE; DRUG WITHDRAWAL; EUROPE; EXTRAPULMONARY TUBERCULOSIS; GRANULOMA; HEART FAILURE; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOGENICITY; INFECTION; INFLAMMATION; INJECTION SITE REACTION; LIVER FAILURE; LIVER TOXICITY; LOADING DRUG DOSE; LONG TERM CARE; LOW DRUG DOSE; LUNG TUBERCULOSIS; LUPUS LIKE SYNDROME; LUPUS VULGARIS; LYMPHOMA; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; MYCOSIS; PANCYTOPENIA; PATHOGENESIS; PATIENT CARE; PNEUMONIA; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROTOZOAL INFECTION; PRURITUS; PSORIASIS; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DEFECT; SOLID TUMOR; STEADY STATE; SYSTEMATIC REVIEW; T CELL LYMPHOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; TUBERCULOSIS; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VASCULITIS; VIRUS INFECTION;

EID: 34250368782     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.2.3.335     Document Type: Review

References (89)

1. Krueger G, Callis K. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch. Dermatol, 140, 218-225 (2004).
2. Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology, tumor necrosis factor α (TNF-α) blockade in psoriasis and psoriatic arthritis. Clin. Dermatol, 21, 392-397 (2003).
3. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum. 36, 159-167 (2006).
4. Lizzul PF, Aphale A, Malaviya R et al. Differential expression of phosphorylated NF-κB/RelA in normal and psoriatic epidermis and downregulation of NF-κB in response to treatment with etanercept. J. Invest Dermatol, 124, 1275-1283 (2005).
5. Enbrel® Package Insert (US FDA - label approved June 2006).
6. Enbrel® Package Insert (EMEA - Rev. 14, published December 2006).
7. Remicade® Package Insert (US FDA - label approved October 2006).
8. Remicade® Package Insert (EMEA - Rev. 13, published November 2006).
9. Humira® Package Insert (US FDA - label approved February 2007).
10. Humira® Package Insert (EMEA - Rev. 4, published November 2006).
11. Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol, Exp. Ther. 301, 418-426 (2002).
12. Shen C, Assche GV, Colpaert S et al. Adalimumab induces apoptosis, of human monocytes: a comparative study with infliximab and etanercept. Aliment. Pharmacol Ther. 21, 251-258 (2005).
13. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin. Arthritis Rheum. 34(5 Suppl. 1), 12-18 (2005).
14. Rojas JR, Taylor RP, Cunningham MR et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 113, 578-585 (2005).
15. Ogilvie AL, Luftl M, Antoni C, Schuler G, Kalden JR, Lorenz HM. Leukocyte infiltration and mRNA expression of IL-20 IL-8 and TNF-R P60 in psoriatic skin is driven by TNF-α. Int. J. Immunolpathol. Pharmacol 19, 271-278 (2006)
16. Cordiali-Fei P, Trento E, D'Agosto et al. Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-α. J. Autoimmune Dis (2006).
17. Markham T, Mullan R, Golden-Mason L et al. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J. Am. Acad. Dermatol. 546, 1003-1012 (2006).
18. Goedkoop AY, Kraan MC, Picavet DI et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res. Ther. 6, R326-R334 (2004).
19. Goedkoop AY, Kraan MC, Teunissen MB et al. Early effects of tumour necrosis factor α blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann. Rheum. Dis. 63, 769-773 (2004).
20. Malaviya R, Sun Y, Tan JK, Magliocco M, Gottlieb AB. Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis. J. Drugs Dermatol. 5, 890-893 (2006).
21. Markham T, Mathews C, Rogers S et al. Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy. Br. J. Dermatol. 155, 1191-1196 (2006).
22. Kruger-Krasagakis S, Galanopoulos VK. Giannikaki L, Stefanidou M, Tosca AD. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis. Br. J. Dermatol. 154, 460-466 (2006).
23. Bovenschen HJ, Van De Kerkhof PC, Gerritsen WJ, Seyger MM. The role of lesional T cells in recalcitrant psoriasis during infliximab therapy. Eur J. Dermatol. 15, 454-458 (2005).
24. Gottlieb AB, Chamian F, Masud S et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J. Immunol. 175, 2721-2729 (2005).
25. Malaviya R, Sun Y, Tan J et al. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J. Am. Acad. Dermatol. 55, 590-597 (2006).
26. Gordon KB, Bonish BK, Patel T, Leonardi CL, Nickoloff BJ. The tumour necrosis factor-α inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br. J. Dermatol. 153, 945-953 (2005).
27. Riccieri V, Spadaro A, Taccari E et al. Analisi immunoistochimica dell'espressione delle principali molecole di adesione e dei fattori di necrosi tumorale a livello della membrana sinoviale nell'artrite psoriasica. Reumatismo 55,164-170 (2003).
28. Hashigucci K, Yokoyama M, Niizeki H et al. Polymorphism in the tumor necrosis factor B gene is associated with palmoplantar pustulosis. Tissue Antigens 54, 288-290 (1999).
29. Kim TG, Pyo CW, Hur SS et al. Polymorphisms of tumor necrosis factor (TNF) α and β genes in Korean patients with psoriasis. Arch. Dermatol. Res. 295, 8-13 (2003).
30. Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol. 139, 1627-1632 (2003).
31. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349, 2014-2022 (2003).
32. Papp KA, Tyring S, Lahfa M et al. A global Phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol. 152, 1304-1312 (2005).
33. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357, 1842-1847 (2001).
34. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 51, 534-542 (2004).
35. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a Phase III, multicentre, double-blind trial. Lancet 366, 1367-1374 (2005).
36. Mössner R, Reich K. Infliximab in the treatment of psoriasis. Expert Rev. Dermatol. 1(4), 515-526 (2006).
37. Gratch N, Weinberg JM, Alexis AF. Etanercept: a tumor necrosis factor inhibitor for psoriasis and psoriatic arthritis. Expert Rev. Dermatol. 1(4), 527-534 (2006).
38. Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J. Am. Acad. Dermatol. 55, 598-606 (2006).
39. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52, 3279-3289 (2005).
40. Gladman DD. Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review. Drugs 65, 1223-1238 (2005).
41. Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab improves joint- and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann. Rheum. Dis. 66(2), 163-168 (2007).
42. Elewski B, Leonardi C, Gottlieb AB et al. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Br. J. Dermatol. 156, 138-142 (2007).
43. Cassano N, Loconsole F, Galluccio, A et al. Once-weekly administration of high-dosage etanercept in patients with plaque psoriasis: results of a pilot experience (POWER study). Int. J. Immunopathol. Pharmacol. 19, 225-229 (2006).
44. Gordon KB, Gottlieb AB, Leonardi CL et al. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J. Dermatol. Treat. 17, 9-17 (2006).
45. Moore A, Gordon KB, Kang S et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J. Am. Acad. Dermatol. 56(4), 598-603 (2007).
46. Leonardi C, Boh E, Langley R, Krueger G. Assessment of response variability in patients treated with step-down etanercept therapy over 48 weeks. J. Am. Acad. Dermatol. 54(Suppl. 3), 2861 (2006).
47. Tyring S, Poulin Y, Langley R, Gordon K. A 96-week Phase 3 study of safety and efficacy of etanercept 50 mg twice weekly in patients with psoriasis. J. Am. Acad. Dermatol. 54(Suppl. 3), 39 (2006).
48. de Groot M, Appelman M, Spuls PI, de Rie MA, Bos JD. Initial experience with routine administration of etanercept in psoriasis. Br. J. Dermatol. 155, 808-814 (2006).
49. Strober B, Gottlieb AB, Johnson R, Leonardi C, Papp K. Levels of response of psoriasis patients with different baseline characteristics treated with etanercept. J. Am. Acad. Dermatol. 54(Suppl. 3), 2890 (2006).
50. Gottlieb AB, Chaudhari U, Mulcahy LD, Li S, Dooley LT, Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J. Am. Acad. Dermatol. 48, 829-835 (2003).
51. Cassano N, Loconsole F, Amoruso A et al. Infliximab monotherapy for refractory psoriasis: preliminary results. Int. J. Immunopathol. Pharmacol. 17, 373-380 (2004).
52. Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease - seven years on. Aliment. Pharmacol. Ther. 23, 451-463 (2006).
53. Menter A, Feldman SR, Weinstein GD et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J. Am. Acad. Dermatol. 56, 31.e1-31e.15 (2007).
54. Kalb RE, Gurske J. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo. J. Am. Acad. Dermatol. 53, 616-622 (2005).
55. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab. Arthritis Rheum. 54, 3782-3789 (2006).
56. Krueger GG, Elewski B, Papp K, Wang A, Zitnik R, Jahreis A. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial. J. Am. Acad. Dermatol. 54(3 Suppl. 2), S112-S119 (2006).
57. Papp K, Griffiths CEM, Li S, Guzzo C. Achievement of response after initial partial or lack of response to infliximab therapy in psoriasis patients: data from EXPRESS and EXPRESS II. J. Am. Acad. Dermatol. 54(Suppl. 3), 2854 (2006).
58. Cather JC, Menter A. Combining traditional agents and biologics for the treatment of psoriasis. Semin. Cutan. Med. Surg. 24, 37-45 (2005).
59. Jacob SE, Sergay A, Kerdel FA. Etanercept and psoriasis, from clinical studies to real life. Int. J. Dermatol. 44, 688-691 (2005).
60. Yamauchi PS, Lowe NJ. Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis. J. Am. Acad. Dermatol. 54(3 Suppl. 2), S135-S138 (2006).
61. Gomez-Reino JJ, Carmona L; BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res. Ther. 8, R29 (2006).
62. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 56, 13-20 (2006).
63. Cohen JD, Bournerias I, Buffard V et al. Psoriasis induced by tumor necrosis factor-α antagonist therapy: a case series. J. Rheumatol. 34(2), 380-385 (2007).
64. Goiriz R, Dauden E, Perez-Gala S, Guhl G, Garcia-Diez A. Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers. Clin. Exp. Dermatol. 32(2), 176-179 (2006).
65. Cassano N, Coviello C, Loconsole F, Miracapillo A, Vena GA. Psoriasis exacerbation after a flu-like syndrome during anti-TNF-α therapy. Eur. J. Dermatol. 16, 316-317 (2006).
66. Kamarashev J, Lor P, Forster A, Heinzerling L, Burg G, Nestle FO. Generalised pustular psoriasis induced by cyclosporine A withdrawal responding to the tumour necrosis factor α inhibitor etanercept. Dermatology 205, 213-216 (2002).
67. Trent JT, Kerdel FA, Successful treatment of Von Zumbusch pustular psoriasis with infliximab. J. Cutan. Med. Surg. 8, 224-228 (2004).
68. Callen JP, Jackson JH. Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent. J. Dermatol. Treat. 16, 350-352 (2005).
69. Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S. Treatment of erythrodermic psoriasis with etanercept. Br. J. Dermatol. 155, 156-159 (2006).
70. Weisenseel P, Prinz JC. Sequential use of infliximab and etanercept in generalized pustular psoriasis. Cutis 78, 197-199 (2006).
71. Bonish B, Rashid RM, Swan J. Etanercept responsive acrodermatitis continua of Hallopeau: is a pattern developing? J. Drugs Dermatol. 5, 903-904 (2006).
72. Menter MA, Cush JM. Successful treatment of pediatric psoriasis with infliximab. Pediatr. Dermatol. 21, 87-88 (2004).
73. Papoutsaki M, Costanzo A, Mazzotta A, Gramiccia T, Soda R, Chimenti S. Etanercept for the treatment of severe childhood psoriasis. Br. J. Dermatol. 154, 181-183 (2006).
74. Desay SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract. Res. Clin. Rheumatol. 20, 7757-7790 (2006).
75. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 52, 1766-1772 (2005).
76. Orenstein R. Infections related to TNF-α inhibitors. Expert Rev. Dermatol. 1(5), 737-749 (2006).
77. Zein NN; Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a Phase 2 randomized, double-blind, placebo-controlled study. J. Hepatol. 42, 315-322 (2005).
78. Ting PT, Koo JY. Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. Int. J. Dermatol. 45, 689-692 (2006).
79. Geborek P, Bladstrom A, Turesson C et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann. Rheum. Dis. 64, 699-703 (2005).
80. Askling J, Fored CM, Baecklund E et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann. Rheum. Dis. 64, 1414-1420 (2005).
81. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J. Invest. Dermatol. 126, 2194-2201 (2006).
82. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. 138, 807-811 (2003).
83. Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 190, 1-9 (2007).
84. Magnano MD, Robinson WH, Genovese MC. Demyelination and inhibition of tumor necrosis factor (TNF). Clin. Exp. Rheumatol. 22 (5 Suppl. 35), S134-S140 (2004).
85. De Bandt M. Lessons for lupus from tumour necrosis factor blockade. Lupus 15, 762-767 (2006).
86. Katz JA, Antoni CE, Keenan GF et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease or rheumatoid arthritis. Am. J. Gastroenterol. 99, 2385-2392 (2004).
87. Koksvik HS, Magnussen AS, Skomsvoll JF. One year follow-up of etanercept exposed pregnancies. Ann. Rheum. Dis. 64 (Suppl. 3), 449 (2005).
88. Vena GA, Cassano N. Emerging drugs for psoriasis. Expert. Opin. Emerg. Drugs 11, 567-596 (2006).
89. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis. Br. J. Dermatol. 153, 486-497 (2005).